Pembrolizumab Plus Ipilimumab Vs Pembrolizumab Plus Placebo As 1l Therapy For Metastatic Nsclc Of Pd-L1 Tps >= 50%: Keynote-598

JOURNAL OF THORACIC ONCOLOGY(2021)

引用 1|浏览6
暂无评分
关键词
Phase III trial, Relapsed Malignant Mesothelioma, Immune-checkpoint-inhibitor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要